[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radio-dermatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radio-dermatitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100639326","polarized-light-therapy-for-radiation-dermatitis-in-breast-cancer-100639326",false,"NCT07600957","Polarized Light Therapy for Radiation Dermatitis in Breast Cancer","Efficacy of Polarized Polychromatic Light Therapy on Acute Radiation Dermatitis in Breast Cancer Patients: A Randomized Controlled Trial","PLARD-BREAST","Inclusion Criteria:\n\n1. Female patients aged 35-55 years.\n2. Histologically confirmed primary unilateral breast cancer.\n3. Status post breast-conserving surgery (lumpectomy).\n4. Planned for hypo fractionated whole-breast irradiation (HFWBI).\n5. Scheduled to receive a total radiation dose of 40-42.5 Gy delivered in 15-16 fractions over approximately 3 weeks.\n6. Ability to understand study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n1. Previous radiotherapy to the same breast or thoracic region.\n2. Bilateral breast cancer.\n3. Metastatic or advanced systemic disease.\n4. Prior mastectomy.\n5. Active skin infection in the irradiated area.\n6. Pre-existing dermatologic disorders affecting the breast skin (e.g., eczema, psoriasis, dermatitis).\n7. Concurrent chemotherapy during radiotherapy.\n8. Presence of cardiac pacemaker or implantable electronic device in the treatment field.\n9. Open wounds or ulceration in the irradiated breast region.\n10. Any medical condition judged by the investigator to interfere with study participation or outcome assessment.","FEMALE","35 Years","55 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This assessor-blinded randomized controlled trial aims to evaluate the efficacy of polarized polychromatic non-coherent light therapy as an adjunct to standard skin care in reducing acute radiation dermatitis in women with breast cancer undergoing hypofractionated whole-breast radiotherapy. Participants will be randomly allocated to receive either standard skin care alone or standard care combined with polarized light therapy initiated from the first radiotherapy session. Outcomes will include objective ultrasound-based dermal thickness measurements, clinical severity of radiation dermatitis using Radiation Therapy Oncology Group (RTOG) criteria.",[28,29,30],"Radio Dermatitis","Polarized Light","Breast Cancer Survivors",[32,33,34,35],"hypo fractionated whole-breast irradiation","radiodermatitis","polarized light therapy","ultrasound scan","RECRUITING","2026-05-21",{"date":39,"type":40},"2026-05-26","ACTUAL",{"date":37,"type":40},{"date":43,"type":22},"2027-01-31",{"name":45,"class":46},"Beni-Suef University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100607031","using-red-light-therapy-to-ease-skin-side-effects-and-mouth-side-effects-in-children-and-young-people-aged-0-to-16-years-old-receiving-radiotherapy-100607031","NCT07183267","Using Red Light Therapy to Ease Skin Side Effects and Mouth Side Effects, in Children and Young People Aged 0 to 16 Years Old, Receiving Radiotherapy","Reducing rAdiation aDverse Effects of dermatitIs and mucosAl inflammatioN Using Red Light Therapy","RADIANT","Inclusion Criteria:\n\n* Paediatric patient receiving a treatment course of either proton or photon therapy - Craniospinal treatment field, Head and Neck treatment fields and body treatment fields.\n\nExclusion Criteria:\n\n* Paediatric patients receiving focal brain only proton or photon radiotherapy.\n* Paediatric patients receiving a single fraction of proton or photon therapy.\n* Total Body Irradiation patients.","ALL","0 Years","16 Years",{"count":60,"type":22},248,[25],"The goal of this interventional study is to see if the daily use of red light therapy called photobiomodulation can help sore skin and sore mouths in children having radiotherapy.\n\nAll children aged 0-16 years old who are receiving either proton or photon radiotherapy treatment, except to the brain only, will be asked if they would like to join the study.\n\nThe main questions it aims to answer are:\n\n1. Does the use of red light therapy help the skin side effects in children and young people undergoing proton or photon therapy?\n2. Does the use of red light therapy help the mouth side effects in children and young people undergoing proton or photon therapy in the head and neck area?\n\nResearchers will compare the patients enrolled on to the study with a like for like historic patient to see if red light therapy improves the sore skin and sore mouths caused by proton or photon therapy.\n\nParticipants will have a daily treatment with red light therapy alongside their daily proton or photon treatment fraction.",[28,64,65],"Mucositis Oral","Oesophagitis",[67,68,69,70,71],"Paediatric skin toxicity","paediatric oral mucositis","paediatric proton therapy","paediatric radiotherapy","paediatric photon therapy","NOT_YET_RECRUITING","2026-03-17",{"date":75,"type":40},"2026-03-19",{"date":77,"type":22},"2026-06-01",{"date":79,"type":22},"2028-10-01",{"name":81,"class":46},"The Christie NHS Foundation Trust",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":56,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":114},"100592187","photobiomodulation-in-radiodermatitis-in-people-with-breast-cancer-100592187","NCT06990165","Photobiomodulation in Radiodermatitis in People With Breast Cancer","Efficacy of Photobiomodulation in the Prevention and Severity of Radiodermatitis in People With Breast Cancer Undergoing Adjuvant Radiotherapy","Inclusion Criteria:\n\n* Individuals aged 18 years or older with an indication for adjuvant radiotherapy for breast cancer treatment at National Cancer Institute (INCA-BRAZIL).\n\nExclusion Criteria:\n\n* Previous diagnosis of cancer or bilateral breast cancer.\n* Oncological treatment outside the institution.\n* Connective tissue disorders (such as scleroderma and lupus erythematosus).\n* Previous radiotherapy to the breast or chest wall.\n* Individuals unable to complete the questionnaires.\n* Individuals unable to receive photobiomodulation due to acute infections.","18 Years",{"count":91,"type":22},148,[25],"Most breast cancer patients undergoing radiotherapy develop radiodermatitis, making it one of the most prevalent adverse events during cancer treatment. The severity of radiodermatitis can pose a life-threatening risk to patients, lead to functional limitations, delay treatment (pauses for tissue recovery), reduce the radiation dose, and negatively impact health-related quality of life. There is no consensus on the ideal strategy for preventing radiodermatitis.\n\nPhotobiomodulation is a non-invasive strategythat may stimulate skin regeneration and minimize radiodermatitis without interfering with cancer treatment, with minimal risk (it may cause rare allergic-type complications or discomfort due to material contact) and low cost for both the patient and the healthcare system, making this approach highly relevant.\n\nReducing the use of pharmaceuticals, the duration of radiotherapy treatment, and the costs associated with managing radiodermatitis will have socioeconomic and environmental impacts, as this is a sustainable, safe, and cost-effective therapeutic approach with high applicability and clinical reproducibility.\n\nAdditionally, it can later be expanded to other types of cancer. This study hypothesizes that photobiomodulation can prevent and reduce complications associated with radiodermatitis in breast cancer patients undergoing adjuvant radiotherapy.\n\nTherefore, the primary objective of this clinical trial is to assess the efficacy of photobiomodulation in preventing and reducing the severity of radiodermatitis in breast cancer patients receiving adjuvant radiotherapy at Hospital do Câncer III of the Brazilian National Cancer Institute.\n\nThe secondary objectives include evaluating the incidence and severity grades of radiodermatitis; comparing the influence of photobiomodulation, according to the intervention group, on the occurrence and severity of radiodermatitis, pain, edema\u002Flymphedema, paresthesia, functionality, skin quality, health-related quality of life, and sleep quality after radiotherapy; comparing the recovery time of radiodermatitis between groups; and assessing satisfaction, safety, and tolerability of photobiomodulation use.",[95,28],"Breast Cancer",[97,98,99,100,101,102,103],"Physical Therapy","Phototherapy","Low-Level Light Therapy","Radiodermatitis","Adverse effects","Radiotherapy Adjuvant","Breast Neoplasms","2025-05-16",{"date":106,"type":40},"2025-05-25",{"date":108,"type":22},"2025-05",{"date":110,"type":22},"2029-04",{"name":112,"class":113},"Instituto Nacional de Cancer, Brazil","OTHER_GOV",2]